The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Commentary|Articles|August 21, 2025
AI Is Already Aiding Clinical Practice Across the Cancer Care Continuum
Author(s)Kyle Doherty
Fact checked by: Chris Ryan
Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.
Advertisement
Advertisement
The use of artificial intelligence (AI) is rapidly expanding in oncologic clinical practice, with applications including expediting administrative tasks, risk-stratification testing, research, and assistance with interpreting pathology and imaging results.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement